AU2003218586B2 - Method of identifying transmembrane protein-interacting compounds - Google Patents

Method of identifying transmembrane protein-interacting compounds Download PDF

Info

Publication number
AU2003218586B2
AU2003218586B2 AU2003218586A AU2003218586A AU2003218586B2 AU 2003218586 B2 AU2003218586 B2 AU 2003218586B2 AU 2003218586 A AU2003218586 A AU 2003218586A AU 2003218586 A AU2003218586 A AU 2003218586A AU 2003218586 B2 AU2003218586 B2 AU 2003218586B2
Authority
AU
Australia
Prior art keywords
receptor
cell
nls
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2003218586A
Other languages
English (en)
Other versions
AU2003218586A1 (en
Inventor
Susan R. George
Brian F. O'dowd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Omeros Corp
Original Assignee
Omeros Medical Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omeros Medical Systems Inc filed Critical Omeros Medical Systems Inc
Publication of AU2003218586A1 publication Critical patent/AU2003218586A1/en
Assigned to PATOBIOS LIMITED reassignment PATOBIOS LIMITED Request for Assignment Assignors: GEORGE, SUSAN, O'DOWD, BRIAN
Application granted granted Critical
Publication of AU2003218586B2 publication Critical patent/AU2003218586B2/en
Priority to AU2009201195A priority Critical patent/AU2009201195B2/en
Assigned to OMEROS CORPORATION reassignment OMEROS CORPORATION Request for Assignment Assignors: PATOBIOS LIMITED
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AU2003218586A 2002-04-12 2003-04-11 Method of identifying transmembrane protein-interacting compounds Expired AU2003218586B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009201195A AU2009201195B2 (en) 2002-04-12 2009-03-26 Method of Identifying Transmembrane Protein-Interacting Compounds

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US37170402P 2002-04-12 2002-04-12
US60/371,704 2002-04-12
US37941902P 2002-05-13 2002-05-13
US60/379,419 2002-05-13
US38757002P 2002-06-12 2002-06-12
US60/387,570 2002-06-12
US42289102P 2002-11-01 2002-11-01
US60/422,891 2002-11-01
US44255603P 2003-01-27 2003-01-27
US60/442,556 2003-01-27
PCT/CA2003/000542 WO2003087836A1 (en) 2002-04-12 2003-04-11 Method of identifying transmembrane protein-interacting compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2009201195A Division AU2009201195B2 (en) 2002-04-12 2009-03-26 Method of Identifying Transmembrane Protein-Interacting Compounds

Publications (2)

Publication Number Publication Date
AU2003218586A1 AU2003218586A1 (en) 2003-10-27
AU2003218586B2 true AU2003218586B2 (en) 2009-01-08

Family

ID=29255685

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003218586A Expired AU2003218586B2 (en) 2002-04-12 2003-04-11 Method of identifying transmembrane protein-interacting compounds
AU2009201195A Expired AU2009201195B2 (en) 2002-04-12 2009-03-26 Method of Identifying Transmembrane Protein-Interacting Compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009201195A Expired AU2009201195B2 (en) 2002-04-12 2009-03-26 Method of Identifying Transmembrane Protein-Interacting Compounds

Country Status (16)

Country Link
US (8) US7309576B2 (cg-RX-API-DMAC7.html)
EP (3) EP2073013B1 (cg-RX-API-DMAC7.html)
JP (4) JP4542342B2 (cg-RX-API-DMAC7.html)
CN (1) CN100399028C (cg-RX-API-DMAC7.html)
AT (1) ATE421697T1 (cg-RX-API-DMAC7.html)
AU (2) AU2003218586B2 (cg-RX-API-DMAC7.html)
CA (1) CA2521946C (cg-RX-API-DMAC7.html)
CY (1) CY1108997T1 (cg-RX-API-DMAC7.html)
DE (1) DE60325953D1 (cg-RX-API-DMAC7.html)
DK (1) DK1495330T3 (cg-RX-API-DMAC7.html)
ES (2) ES2566487T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA04011134A (cg-RX-API-DMAC7.html)
NZ (2) NZ567458A (cg-RX-API-DMAC7.html)
PT (1) PT1495330E (cg-RX-API-DMAC7.html)
SI (1) SI1495330T1 (cg-RX-API-DMAC7.html)
WO (1) WO2003087836A1 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2521946C (en) * 2002-04-12 2013-10-15 Brian F. O'dowd Method of identifying transmembrane protein-interacting compounds
EP2138195A3 (en) * 2004-06-16 2010-07-21 Affinergy Inc. IFBM's to promote attachment of target analytes
CN1944647B (zh) * 2006-08-23 2010-05-12 华东师范大学 多巴胺受体新亚型d5b基因及编码的蛋白与应用
JP4929462B2 (ja) 2007-01-29 2012-05-09 国立大学法人高知大学 細胞膜上分子と相互作用する化合物の検出方法
JP5213075B2 (ja) 2007-06-15 2013-06-19 ジェネラックス・コーポレイション 腫瘍の画像化および／または処置のための微生物
JP5230397B2 (ja) * 2008-12-18 2013-07-10 独立行政法人科学技術振興機構 抗膜貫通型タンパク質抗体の抗原結合部位を決定する方法
CN102580091B (zh) * 2011-01-12 2014-12-10 中国科学院上海生命科学研究院 增强阿片镇痛剂的镇痛作用的方法及试剂
US8643360B1 (en) * 2012-09-02 2014-02-04 George S. Cargill, III In-water voltage gradient detector
TWI472617B (zh) * 2012-09-17 2015-02-11 Nat Univ Chung Hsing 調控大分子進入細胞內之蛋白質及其調控大分子進入細胞內之方法
US10513711B2 (en) 2014-08-13 2019-12-24 Dupont Us Holding, Llc Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
CA2966731C (en) 2014-11-06 2023-01-31 E. I. Du Pont De Nemours And Company Peptide-mediated delivery of rna-guided endonuclease into cells
CA2985506A1 (en) 2015-05-15 2016-11-24 Pioneer Hi-Bred International, Inc. Guide rna/cas endonuclease systems
WO2017066175A1 (en) 2015-10-12 2017-04-20 E. I. Du Pont De Nemours And Company Protected dna templates for gene modification and increased homologous recombination in cells and methods of use
EP3365439A1 (en) 2015-10-20 2018-08-29 Pioneer Hi-Bred International, Inc. Methods and compositions for marker-free genome modification
WO2017079026A1 (en) 2015-11-06 2017-05-11 E. I. Du Pont De Nemours And Company Generation of complex trait loci in soybean and methods of use
WO2017100158A1 (en) 2015-12-11 2017-06-15 Danisco Us Inc. Methods and compositions for enhanced nuclease-mediated genome modification and reduced off-target site effects
WO2017105991A1 (en) 2015-12-18 2017-06-22 Danisco Us Inc. Methods and compositions for t-rna based guide rna expression
BR112018015348A2 (pt) 2016-01-26 2018-12-18 Pioneer Hi Bred Int método para obter uma planta de milho ceroso, planta, semente, polinucleotídeo-guia e método para produzir uma planta híbrida de milho ceroso
WO2017155715A1 (en) 2016-03-11 2017-09-14 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
US20190161742A1 (en) 2016-03-11 2019-05-30 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
EP3426778A1 (en) 2016-03-11 2019-01-16 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
CA3022854A1 (en) 2016-06-14 2017-12-21 Pioneer Hi-Bred International, Inc. Use of cpf1 endonuclease for plant genome modifications
CA3018430A1 (en) 2016-06-20 2017-12-28 Pioneer Hi-Bred International, Inc. Novel cas systems and methods of use
EP4242330A3 (en) 2016-10-13 2023-11-22 Pioneer Hi-Bred International, Inc. Generating northern leaf blight resistant maize
EP3551745A4 (en) * 2016-12-12 2020-07-15 Xcella Biosciences, Inc. SCREENING METHODS AND SYSTEMS USING MICROCAPILLARY NETWORKS
US11156626B2 (en) 2016-12-30 2021-10-26 xCella Biosciences, Inc. Multi-stage sample recovery system
US11519009B2 (en) 2017-01-09 2022-12-06 University Of Massachusetts Complexes for gene deletion and editing
EP3707253A1 (en) 2017-12-15 2020-09-16 Danisco US Inc. Cas9 variants and methods of use
CN108178790B (zh) * 2018-01-18 2021-09-07 上海药明康德新药开发有限公司 一种将细胞膜分离以便对跨膜蛋白进行dna编码化合物库筛选的方法
WO2019165168A1 (en) 2018-02-23 2019-08-29 Pioneer Hi-Bred International, Inc. Novel cas9 orthologs
WO2020081173A1 (en) 2018-10-16 2020-04-23 Pioneer Hi-Bred International, Inc. Genome edited fine mapping and causal gene identification
US12318775B2 (en) 2018-12-06 2025-06-03 xCella Biosciences, Inc. Lateral loading of microcapillary arrays
CN113166744B (zh) 2018-12-14 2025-02-07 先锋国际良种公司 用于基因组编辑的新颖crispr-cas系统
AU2020205753B2 (en) 2019-01-11 2025-05-29 Omeros Corporation Methods and compositions for treating cancer
EP3947656A1 (en) 2019-04-05 2022-02-09 Danisco US Inc. Methods for polynucleotide integration into the genome of bacillus using dual circular recombinant dna constructs and compositions thereof
CA3136114A1 (en) 2019-04-05 2020-10-08 Danisco Us Inc. Methods for integrating a donor dna sequence into the genome of bacillus using linear recombinant dna constructs and compositions thereof
KR102329302B1 (ko) * 2019-09-30 2021-11-22 한국과학기술연구원 도파민 d1형 수용체의 활성 측정용 적색 형광 단백질 기반 바이오센서
WO2023105244A1 (en) 2021-12-10 2023-06-15 Pig Improvement Company Uk Limited Editing tmprss2/4 for disease resistance in livestock
KR102833970B1 (ko) * 2022-02-23 2025-07-17 충남대학교산학협력단 핵수송 신호 펩타이드가 접합된 핵산 전달용 2세대 폴리아미도아민 덴드리머 고분자 유도체
WO2024013514A2 (en) 2022-07-15 2024-01-18 Pig Improvement Company Uk Limited Gene edited livestock animals having coronavirus resistance
WO2024118881A1 (en) 2022-12-01 2024-06-06 Genencor International Bv Iterative muliplex genome engineering in microbial cells using a bidirectional selection marker system
WO2024118882A1 (en) 2022-12-01 2024-06-06 Genencor International Bv Iterative multiplex genome engineering in microbial cells using a selection marker swapping system
WO2024118876A1 (en) 2022-12-01 2024-06-06 Genencor International Bv Iterative multiplex genome engineering in microbial cells using a recombinant self-excisable selection marker system
KR20250160500A (ko) 2023-03-20 2025-11-13 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 변경된 pam 인식을 갖는 cas 폴리펩티드

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030022277A1 (en) * 1995-05-05 2003-01-30 Daniel R. Soppet Human neuropeptide receptor
US6004808A (en) * 1996-06-21 1999-12-21 Aurora Biosciences Corporation Promiscuous G-protein compositions and their use
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US6383761B2 (en) * 1997-07-28 2002-05-07 The Regents Of The University Of California Methods and compositions for identifying modulators of G-protein-coupled receptors
AU2001241463A1 (en) * 2000-02-09 2001-08-20 Human Genome Sciences, Inc. Human g-protein chemokine receptor (CCR5) HDGNR10
WO2002014475A2 (en) 2000-08-16 2002-02-21 The Trustees Of Columbia University In The City Of New York QUANTITATIVE ASSESSMENT OF erbB/HER RECEPTORS IN BIOLOGICAL FLUIDS
CA2521946C (en) 2002-04-12 2013-10-15 Brian F. O'dowd Method of identifying transmembrane protein-interacting compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chen, R. et al. (2000) American Journal of Renal Physiology 279: F440-F448 *

Also Published As

Publication number Publication date
EP2339347A1 (en) 2011-06-29
JP2010112955A (ja) 2010-05-20
US20050287602A1 (en) 2005-12-29
US20090081691A1 (en) 2009-03-26
ES2321704T3 (es) 2009-06-10
HK1128957A1 (en) 2009-11-13
AU2003218586A1 (en) 2003-10-27
US20180267051A1 (en) 2018-09-20
ES2566487T3 (es) 2016-04-13
MXPA04011134A (es) 2005-08-15
JP6168669B2 (ja) 2017-07-26
NZ567458A (en) 2009-10-30
JP5187910B2 (ja) 2013-04-24
WO2003087836A1 (en) 2003-10-23
ATE421697T1 (de) 2009-02-15
HK1073358A1 (en) 2005-09-30
JP5870016B2 (ja) 2016-02-24
EP2073013B1 (en) 2016-01-06
SI1495330T1 (sl) 2009-06-30
AU2009201195B2 (en) 2012-05-03
EP2073013A1 (en) 2009-06-24
US20150377896A1 (en) 2015-12-31
JP2016026299A (ja) 2016-02-12
DE60325953D1 (de) 2009-03-12
US8298777B2 (en) 2012-10-30
US20100279318A1 (en) 2010-11-04
JP4542342B2 (ja) 2010-09-15
CY1108997T1 (el) 2014-07-02
EP1495330A1 (en) 2005-01-12
US7309576B2 (en) 2007-12-18
JP2013137311A (ja) 2013-07-11
AU2009201195A1 (en) 2009-04-23
JP2005522227A (ja) 2005-07-28
CN1646917A (zh) 2005-07-27
US20170336418A1 (en) 2017-11-23
US7794955B2 (en) 2010-09-14
US9005905B2 (en) 2015-04-14
NZ536063A (en) 2008-08-29
US20190317105A1 (en) 2019-10-17
PT1495330E (pt) 2009-04-23
CA2521946A1 (en) 2003-10-23
CN100399028C (zh) 2008-07-02
US20130084581A1 (en) 2013-04-04
DK1495330T3 (da) 2009-05-18
EP1495330B1 (en) 2009-01-21
CA2521946C (en) 2013-10-15

Similar Documents

Publication Publication Date Title
AU2003218586B2 (en) Method of identifying transmembrane protein-interacting compounds
DK2870475T3 (en) FLUORESCING FUSION POLYPEPTIDE, BIOSENSOR INCLUDING POLYPEPTIDE AND APPLICATIONS THEREOF
AU2012207061B2 (en) Method of Identifying Transmembrane Protein-Interacting Compounds
CA2824698C (en) Method of identifying transmembrane protein-interacting compounds
AU2015203835B2 (en) Method of Identifying Transmembrane Protein-Interacting Compounds
HK1128957B (en) Method of identifying transmembrane protein-interacting compounds
HK1073358B (en) Method of identifying transmembrane protein-interacting compounds

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PATOBIOS LIMITED

Free format text: FORMER APPLICANT(S): GEORGE, SUSAN; O'DOWD, BRIAN

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: OMEROS CORPORATION

Free format text: FORMER OWNER WAS: PATOBIOS LIMITED

MK14 Patent ceased section 143(a) (annual fees not paid) or expired